A Phase 1/2 interventional study of Pegzilarginase and Pembrolizumab in Small-cell Lung Cancer, sponsored by Immedica Pharma AB. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Immedica Pharma AB · Phase 1/2, Interventional, and Treatment
Study enrollment was halted early based on ongoing data monitoring; no efficacy analyses were performed
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 367 are open to participants now.
This study's enrollment of 42 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Browse Small Cell Lung Carcinoma studies →Immedica Pharma AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Key Inclusion Criteria:
Have or cytologically confirmed SCLC that meets:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 \& 2
Drug: Pegzilarginase · Drug: Pembrolizumab
Administered IV
Also known as: AEB1102 (Co-ArgI-PEG)
Administered IV
Also known as: MK-3475, Keytruda
Phase 1: Incidence of Treatment-realted Adverse Events as Assessed by CTCAE v4.0
Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
Time frame: Estimated up to 6 months
Phase 2: Incidence of Treatment-related Adverse Events as Assessed by CTCAE v4.0
Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
Time frame: From first treatment up to 24 months
| Milestone | Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|---|
| Started | 0 | 3 | 9 | 4 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 9 | 4 |
| Milestone | Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|---|
| Started | 26 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 26 | 0 | 0 | 0 |
Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
| Participants | Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg |
|---|---|
| Phase 2: Incidence of Treatment-related Adverse Events as Assessed by CTCAE v4.0 | 24 |
Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0.
| Participants | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|
| Phase 1: Incidence of Treatment-realted Adverse Events as Assessed by CTCAE v4.0 | 2 | 8 | 4 |
Collected over From the first dose of study drug continuing through the last study follow-up visit (range of treatment cycles during the study was 1-30 with 4 weeks/cycle). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg | 4/26 (15.4%) | 16/26 (61.5%) | 26/26 (100%) |
| Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Event | Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 1/26 | 1/3 | 0/9 | 0/4 |
| NauseaGastrointestinal disorders | 1/26 | 0/3 | 0/9 | 1/4 |
| VomitingGastrointestinal disorders | 1/26 | 0/3 | 0/9 | 1/4 |
| DehydrationMetabolism and nutrition disorders | 1/26 | 0/3 | 0/9 | 1/4 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/26 | 0/3 | 0/9 | 1/4 |
| Abdominal painGastrointestinal disorders | 1/26 | 0/3 | 1/9 | 0/4 |
| Confusional statePsychiatric disorders | 0/26 | 0/3 | 1/9 | 0/4 |
| AstheniaGeneral disorders | 2/26 | 0/3 | 0/9 | 0/4 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/26 | 0/3 | 0/9 | 0/4 |
| Cardio-respiratory arrestCardiac disorders | 1/26 | 0/3 | 0/9 | 0/4 |
| Event | Phase 2 - Pegzilarginase 0.27 mg/kg Plus Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 14/26 | 3/3 | 4/9 | 4/4 |
| Decreased appetiteMetabolism and nutrition disorders | 11/26 | 1/3 | 3/9 | 4/4 |
| HeadacheNervous system disorders | 1/26 | 3/3 | 3/9 | 2/4 |
| NauseaGastrointestinal disorders | 13/26 | 2/3 | 5/9 | 3/4 |
| FatigueGeneral disorders | 16/26 | 2/3 | 5/9 | 3/4 |
| HyponatraemiaMetabolism and nutrition disorders | 3/26 | 2/3 | 4/9 | 3/4 |
| DizzinessNervous system disorders | 2/26 | 0/3 | 5/9 | 3/4 |
| DepressionPsychiatric disorders | 1/26 | 0/3 | 0/9 | 3/4 |
| DiarrhoeaGastrointestinal disorders | 8/26 | 2/3 | 1/9 | 0/4 |
| Oedema peripheralGeneral disorders | 0/26 | 2/3 | 2/9 | 1/4 |
| Age, Continuous(Years) | Phase 2 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 63.0 ± 8.0 | 63.7 ± 2.5 | 66.4 ± 8.4 | 61.3 ± 7.3 | 63.6 ± 7.7 |
| Sex: Female, Male(Participants) | Phase 2 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | Total |
|---|---|---|---|---|---|
| Female | 16 | 2 | 5 | 2 | 25 |
| Male | 10 | 1 | 4 | 2 | 17 |
| Race (NIH/OMB)(Participants) | Phase 2 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 2 |
| White | 24 | 3 | 8 | 3 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase 2 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 26 | 3 | 9 | 4 | 42 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| ECOG Performance Status(Participants) | Phase 2 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.20 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.27 mg/kg + Pembrolizumab 200 mg | Phase 1 - Pegzilarginase 0.33 mg/kg + Pembrolizumab 200 mg | Total |
|---|---|---|---|---|---|
| 0 | 9 | 0 | 2 | 1 | 12 |
| 1 | 17 | 3 | 7 | 3 | 30 |
| 2 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Study enrollment was halted early based on ongoing data monitoring; no efficacy analyses were performed
Study enrollment was halted early based on ongoing data monitoring; no efficacy analyses were performed
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegzilarginase